

# Public Health Reviews

## Instructions for Authors

### GENERAL INFORMATION

When considering submitting your work to PHR, please first make sure your article fits the Scope of the journal.

You may also look at the PHR archive for related articles and find out more about the suitability of your article for PHR. The archive will be made Open Access with our current publisher in 2021. Due to the large interest, Editors cannot advise on the suitability of the article before submission of the manuscript.

### **Article Processing Charges (due after acceptance for publication):**

APC for PHR comprise of the production costs of the publisher and the editorial costs of the owner, the Swiss School of Public Health (SSPH+). The SSPH+ discounts the editorial costs for first authors from low and middle income countries according to the [research4life](#) country classification (group A and B countries). APC must be confirmed during submission and are due after acceptance for publication:

Article Type	APC (CHF)		
	Regular	Group A	Group B
Systematic Review	1,980	1,400	1,700
Review	1,980	1,400	1,700
Mini Review	1,400	1,200	1,300
Policy Brief	1,400	1,200	1,300
Editorial *	900	900	900
Commentary *	900	900	900

\* free for invited authors

The above fees and discounts are valid for articles submitted on or after February 1, 2021. APCs may be subject to periodic revision. The invoiced APC is the one valid at the time of manuscript submission.

### **Licensing**

All articles are published under a [CC-BY 4.0 license](#). The authors hold the copyright of the article published. Authors who are not allowed to hold the copyright (for example, authors

affiliated with the US government or Commonwealth governments, or WHO), should contact the Editorial Office for adaptations to copyright during or immediately after submission of the article. No changes to the copyright are possible after the publication of an article.

If you are not sure if you or your employer owns the copyright, you should check that you have the legal right to grant the CC-BY license.

### **Open data**

PHR encourages authors to make their datasets on which the conclusions of the paper rely available to readers as Electronic Supplementary Material or in publicly available repositories. Please see Frontiers' information on recommended repositories.

<https://www.frontiersin.org/about/policies-and-publication-ethics#MaterialsDataPolicies>

## **SUBMISSION**

When considering submitting your work to PHR, please first make sure your article fits the Scope of the journal.

The Editors-in-Chief select articles for the peer review mainly based on the title and abstract. The abstract should render the general significance and conceptual advance of the work clearly accessible to a broad readership.

### **Types of papers**

**Public Health Reviews** publishes review articles and policy briefs that contribute to understanding and improving Public Health. PHR does not publish original research or opinion articles. Editorials and Letters to the Editor are welcome. Authors are encouraged to visit the "Article Types" journal page for more information.

We encourage authors to refer to the minimum reporting guidelines for health research hosted by the EQUATOR network when preparing their manuscript. Checklists are available for a number of study designs.

<http://www.equator-network.org/>

## **Manuscript Formatting Guidelines**

### **Article Type**

PHR requires authors to carefully select the appropriate article type for their manuscript and to comply with the article type descriptions defined in the journal's "Article Types" page.

### **Manuscript Length**

PHR encourages the authors to follow the article word count lengths given in the “Article Types” page of the journals. The manuscript length includes only the main body of the text, footnotes, and all citations within it, and excludes the abstract, section titles, figure and table captions, funding statement, acknowledgments, and references in the bibliography. Please indicate the number of words and the number of figures and tables included in your manuscript on the first page.

## Language Style

The default language style at PHR is American English. For any questions regarding style, PHR recommends authors to consult the Chicago Manual of Style.

## Search Engine Optimization (SEO)

There are a few simple ways to maximize your article’s discoverability. Follow the steps below to improve search results of your article:

- include a few of your article's keywords in the title of the article;
- do not use long article titles;
- pick 5 to 8 keywords using a mix of generic and more specific terms on the article subject(s);
- use the maximum amount of keywords in the first 2 sentences of the abstract;
- use some of the keywords in level 1 headings.

## CrossMark Policy

[CrossMark](#) is a multi-publisher initiative to provide a standard way for readers to locate the current version of a piece of content. By applying the CrossMark logo PHR is committed to maintaining the content it publishes and to alerting readers to changes if and when they occur. Clicking on the CrossMark logo will tell you the current status of a document and may also give you additional publication record information about the document.

## Title

The title should be concise, omitting terms that are implicit and, where possible, be a statement of the main result or conclusion presented in the manuscript. Abbreviations should be avoided within the title.

Consider if a title meant to be thought-provoking might be misinterpreted as offensive or alarming. Authors should try to avoid, if possible:

- titles that are a mere question without giving the answer;
- unambitious titles, for example starting with "Towards," "A description of," "A characterization of," "Preliminary study on;"
- vague titles, for example starting with "Role of...," "Link between...," "Effect of..." that do not specify the role, link, or effect;
- include terms that are out of place, for example the taxonomic affiliation apart from species name.

For Corrigenda, the title of your manuscript should have the following format:

- "Corrigendum: Title of Original Article"

The running title should be a maximum of 5 words in length.

## Authors and Affiliations

**Author information should not be included in any submitted files but only in the online data to be completed during the submission process:**

- Corresponding author name, affiliation and email address
- Co-authors (if any - names and affiliation)
- Order of authors

## Author list

The authorship should be clarified thoroughly before submission. Please follow the standard guidelines (e.g. International Committee of Medical Journal Editors , <http://www.icmje.org/>).

Changes of the list of authors or order of authors should be avoided once the manuscript is submitted.

## Abstract

As a primary goal, the abstract should render the general significance and conceptual advance of the work clearly accessible to a broad readership. In the abstract, minimize the use of abbreviations and do not cite references, figures or tables.

## Keywords

All article types require a minimum of 5 and a maximum of 8 keywords.

## Text

The entire document should be single-spaced and must contain page and line numbers in order to facilitate the review process. The manuscript should be written using either Word or LaTeX. **All files must be author blinded. A blinded manuscript should be free from any information that allows the reviewers to identify the authors.**

## Nomenclature

- The use of abbreviations should be kept to a minimum. Non-standard abbreviations should be avoided unless they appear at least four times, and defined upon first use in the main text. Consider also giving a list of non-standard abbreviations at the end, immediately before the Acknowledgments.
- Equations should be inserted in editable format from the equation editor.
- Italicize gene symbols and use the approved gene nomenclature where it is available. For human genes, please refer to the HUGO Gene Nomenclature Committee ([HGNC](http://www.hgnc.org/)). New gene symbols should be submitted [here](#). Common alternative gene aliases may also be reported, but should not be used alone in place

of the HGNC symbol. Nomenclature committees for other species are listed [here](#). Protein products are not italicized.

- We encourage the use of Standard International Units in all manuscripts.
- Chemical compounds and biomolecules should be referred to using systematic nomenclature, preferably using the recommendations by IUPAC.

## Sections

The manuscript is organized by headings and subheadings. The section headings should be those appropriate for your field and the research itself.

## Acknowledgments

This is a short text to acknowledge the contributions of specific funds, colleagues, institutions, or agencies that aided the efforts of the authors. Please omit author names and affiliations from the Acknowledgements. The names of the funding organizations should be written in full (not abbreviated).

## Contribution to the Field Statement

When you submit your manuscript, you will be required to briefly summarize in 200 words your manuscript's contribution to, and position in, the existing literature in your field. This should be written avoiding any technical language or non-standard acronyms. The aim should be to convey the meaning and importance of this research to a non-expert.

Your statement should frame the question(s) you have addressed in your work in the context of the current body of knowledge, providing evidence that the findings—whether positive or negative—contribute to progress in your research discipline. This will assist the Editors-in-Chief to determine whether your manuscript fits within the scope of a specialty as defined in its mission statement; a detailed statement will also facilitate the identification of the editors and reviewers most appropriate to evaluate your work, ultimately expediting your manuscript's initial consideration.

## CC-BY License

All figures, tables, and images will be published under a [Creative Commons CC-BY license](#), and permission must be obtained for use of copyrighted material from other sources (including re-published/adapted/modified/partial figures and images from the internet). It is the responsibility of the authors to acquire the licenses, follow any citation instructions requested by third-party rights holders, and cover any supplementary charges.

## Figure Requirements and Style Guidelines

- PHR requires figures to be submitted individually (author blinded), in the same order as they are referred to in the manuscript; the figures will then be automatically embedded at the end of the submitted manuscript. Kindly ensure that each figure is mentioned in the text and in numerical order.
- For figures with more than one panel, panels should be clearly indicated using labels (A), (B), (C), (D), etc. However, do not embed the part labels over any part of

the image, these labels will be replaced during typesetting according to the journal style. For graphs, there must be a self-explanatory label (including units) along each axis.

- For LaTeX files, figures should be included in the provided PDF. In case of acceptance, our Production Office might require high-resolution files of the figures included in the manuscript in EPS, JPEG or TIF/TIFF format.
- In order to be able to upload more than one figure at a time, save the figures (labeled in order of appearance in the manuscript) in a zip file and upload them as 'Supplementary Material Presentation.'

Please note that figures not in accordance with the guidelines will cause substantial delay during the production process.

## Captions

Captions should be preceded by the appropriate label, for example "Figure 1." Figure captions should be placed at the end of the manuscript. Figure panels are referred to by bold capital letters in brackets: (A), (B), (C), (D), etc.

## Image Size and Resolution Requirements

Figures should be prepared with the PDF layout in mind. Individual figures should not be longer than one page and with a width that corresponds to 1 column (85 mm) or 2 columns (180 mm).

All images must have a resolution of 300 dpi at final size. Check the resolution of your figure by enlarging it to 150%. If the image appears blurry, jagged or has a stair-stepped effect, the resolution is too low.

- The text should be legible and of high quality. The smallest visible text should be no less than 8 points in height when viewed at actual size.
- Solid lines should not be broken up. Any lines in the graphic should be no smaller than 2 points wide.

Please note that saving a figure directly as an image file (JPEG, TIF) can greatly affect the resolution of your image. To avoid this, one option is to export the file as PDF, then convert into TIFF or EPS using a graphics software.

## Format and Color Image Mode

- The following formats are accepted: TIF/TIFF (.tif/.tiff), JPEG (.jpg), and EPS (.eps) (upon acceptance).
- Images must be submitted in the color mode RGB.

## Chemical Structures

Chemical structures should be prepared using ChemDraw or a similar program. If working with another program, please follow the guidelines given below:

- Drawing settings: chain angle, 120° bond spacing, 18% width; fixed length, 14.4 pt; bold width, 2.0 pt; line width, 0.6 pt; margin width, 1.6 pt; hash spacing, 2.5 pt. Scale 100% Atom Label settings: font, Arial; size, 8 pt.

- Assign all chemical compounds a bold, Arabic numeral in the order in which the compounds are presented in the manuscript text.

## Table Requirements and Style Guidelines

- Tables should be inserted at the end of the manuscript in an editable format. If you use a word processor, build your table in Word. If you use a LaTeX processor, build your table in LaTeX. An empty line should be left before and after the table.
- Table captions must be placed immediately before the table. Captions should be preceded by the appropriate label, for example "Table 1." Please use only a single paragraph for the caption.
- Kindly ensure that each table is mentioned in the text and in numerical order.
- Please note that large tables covering several pages cannot be included in the final PDF for formatting reasons. These tables will be published as supplementary material (author blinded).

Please note that tables which are not according to the guidelines will cause substantial delay during the production process.

### Accessibility

PHR encourages authors to make the figures and visual elements of their articles accessible for the visually impaired. An effective use of color can help people with low visual acuity, or color blindness, understand all the content of an article.

These guidelines are easy to implement and are in accordance with the [W3C Web Content Accessibility Guidelines \(WCAG 2.1\)](#), the standard for web accessibility best practices.

#### A. Ensure sufficient contrast between text and its background

People who have low visual acuity or color blindness could find it difficult to read text with low contrast background color. Try using colors that provide maximum contrast.

WC3 recommends the following contrast ratio levels:

- Level AA, contrast ratio of at least 4.5:1
- Level AAA, contrast ratio of at least 7:1

You can verify the contrast ratio of your palette with these online ratio checkers:

- [WebAIM](#)
- [Color Safe](#)

#### B. Avoid using red or green indicators

More than 99% of color-blind people have a red-green color vision deficiency.

#### C. Avoid using only color to communicate information

Elements with complex information like charts and graphs can be hard to read when only color is used to distinguish the data. Try to use other visual aspects to communicate information, such as shape, labels, and size. Incorporating patterns into the shape fills also make differences clearer

## Supplementary Material

Data that are not of primary importance to the text, or which cannot be included in the article because they are too large or the current format does not permit it (such as videos, raw data traces, PowerPoint presentations, etc.), can be uploaded as Supplementary Material during the submission procedure and will be displayed along with the published article. All supplementary files are deposited to Figshare for permanent storage and receive a DOI. **Please ensure all supplementary files are author blinded.**

Supplementary Material is not typeset, so please ensure that all information is clearly presented without tracked changes/highlighted text/line numbers, and the appropriate caption is included in the file. **To avoid discrepancies between the published article and the supplementary material, please do not add the title, author list, affiliations or correspondence in the supplementary files.**

The Supplementary Material can be uploaded as Data Sheet, author blinded (Word, Excel, CSV, CDX, FASTA, PDF or Zip files), Presentation (PowerPoint, PDF or Zip files), Image (CDX, EPS, JPEG, PDF, PNG or TIF/TIFF), Table (Word, Excel, CSV or PDF), Audio (MP3, WAV or WMA) or Video (AVI, DIVX, FLV, MOV, MP4, MPEG, MPG or WMV).

## References

- All citations in the text, figures or tables must be in the reference list and vice-versa.
- The names of the first six authors followed by et al. and the DOI (when available) should be provided.
- The reference list should only include articles that are published or accepted.
- Unpublished data, submitted manuscripts or personal communications should be cited within the text only, for the article types that allow such inclusions.
- For accepted but unpublished works use "in press" instead of page numbers.
- Data sets that have been deposited to an online repository should be included in the reference list. Include the version and unique identifier when available.
- Personal communications should be documented by a letter of permission.
- Website URLs should be included as footnotes.
- Any inclusion of verbatim text must be contained in quotation marks and clearly reference the original source.
- Preprints can be cited as long as a DOI or archive URL is available, and the citation clearly mentions that the contribution is a preprint. If a peer-reviewed journal publication for the same preprint exists, the official journal publication is the preferred source.

## In-text Citations

- Please apply the Vancouver system for in-text citations.
- In-text citations should be numbered consecutively in order of appearance in the text—identified by Arabic numerals in the parenthesis.

## Reference List

## ARTICLE IN A PRINT JOURNAL

Sondheimer N, Lindquist S. Rnq1: an epigenetic modifier of protein function in yeast. *Mol Cell* (2000) 5:163-72.

#### **ARTICLE IN AN ONLINE JOURNAL**

Tahimic CGT, Wang Y, Bikle DD. Anabolic effects of IGF-1 signaling on the skeleton. *Front Endocrinol* (2013) 4:6. doi: 10.3389/fendo.2013.00006

#### **ARTICLE OR CHAPTER IN A BOOK**

Sorenson PW, Caprio JC. "Chemoreception,". In: Evans DH, editor. *The Physiology of Fishes*. Boca Raton, FL: CRC Press (1998). p. 375-405.

#### **BOOK**

Cowan WM, Jessell TM, Zipursky SL. *Molecular and Cellular Approaches to Neural Development*. New York: Oxford University Press (1997). 345 p.

#### **ABSTRACT**

Christensen S, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, editor. *Genetic Programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3–5; Kinsdale, Ireland*. Berlin: Springer (2002). p. 182–91.

#### **WEBSITE**

World Health Organization. *E. coli* (2018). <https://www.who.int/news-room/fact-sheets/detail/e-coli> [Accessed March 15, 2018].

#### **PATENT**

Pagedas AC, inventor; Ancel Surgical R&D Inc., assignee. Flexible Endoscopic Grasping and Cutting Device and Positioning Tool Assembly. United States patent US 20020103498 (2002).

#### **DATA**

Perdiguero P, Venturas M, Cervera MT, Gil L, Collada C. Data from: Massive sequencing of Ulms minor's transcriptome provides new molecular tools for a genus under the constant threat of Dutch elm disease. *Dryad Digital Repository*. (2015)  
<http://dx.doi.org/10.5061/dryad.ps837>

#### **THESES AND DISSERTATIONS**

Smith, J. (2008) Post-structuralist discourse relative to phenomenological pursuits in the deconstructivist arena. [dissertation/master's thesis]. [Chicago (IL)]: University of Chicago

#### **PREPRINT**

Smith, J. Title of the document. Preprint repository name [Preprint] (2008). Available at: <https://persistent-url> (Accessed March 15, 2018).

### **Compliance with ethical standards**

To ensure objectivity and transparency in research and to ensure that accepted principles of ethical and professional conduct have been followed, authors should include information regarding sources of funding, potential conflicts of interest (financial or non-

financial), informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals.

During submission, the submitting author will be required to answer questions regarding the manuscript and research, as well as provide information and consent for all authors. Below is a checklist detailing the information that will be required:

- Conflict of interest (mandatory for all article types)
- Funding (if applicable)
- Ethical approval (including record number) (if applicable)
- Informed consent (if applicable)
- Research involving Human Participants and/or Animals (if applicable)

The corresponding author should be prepared to collect documentation of compliance with ethical standards and send if requested during peer review or after publication. The Editors reserve the right to reject manuscripts that do not comply with the above-mentioned guidelines. The author will be held responsible for false statements or failure to fulfil the above-mentioned guidelines.

## Conflict of interest

Authors must disclose all relationships or interests that could influence or bias the work. Although an author may not feel there are conflicts, disclosure of relationships and interests affords a more transparent process, leading to an accurate and objective assessment of the work. Awareness of real or perceived conflicts of interests is a perspective to which the readers are entitled and is not meant to imply that a financial relationship with an organization that sponsored the research or compensation for consultancy work is inappropriate. Examples of potential conflicts of interests **that are directly or indirectly related to the research** may include but are not limited to the following:

- Research grants from funding agencies (please give the research funder and the grant number)
- Honoraria for speaking at symposia
- Financial support for attending symposia
- Financial support for educational programs
- Employment or consultation
- Support from a project sponsor
- Position on advisory board or board of directors or other type of management relationships
- Multiple affiliations
- Financial relationships, for example equity ownership or investment interest
- Intellectual property rights (e.g. patents, copyrights and royalties from such rights)
- Holdings of spouse and/or children that may have financial interest in the work

In addition, interests that go beyond financial interests and compensation (non-financial interests) that may be important to readers should be disclosed. These may include but are

not limited to personal relationships or competing interests directly or indirectly tied to this research, or professional interests or personal beliefs that may influence your research.

Conflicts of interest should be stated upon submission of an article in the submission system.

The corresponding author will include a summary statement **in the submission system**, that discloses any potential conflict of interest.

See below examples of disclosures:

**Funding:** This study was funded by X (grant number X).

For commercial funding, the role of the funder must be declared. We recommend the following statements:

“The authors declare that this study received funding from XXXXXXXX. The funder had the following involvement with the study: XXXXXXXX”.

“The authors declare that this study received funding from XXXXXXXX. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication”.

**Conflict of interest:** Author A has received research grants from Company A. Author B has received a speaker honorarium from Company X and owns stock in Company Y. Author C is a member of committee Z.

If no conflict exists, the authors should will be able to select the following: *The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.*

## Research involving human participants

### Statement of human rights

When reporting studies that involve human participants, authors should include a statement that the studies have been approved by the appropriate institutional and/or national research ethics committee and have been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

If doubt exists whether the research was conducted in accordance with the 1964 Helsinki Declaration or comparable standards, the authors must explain the reasons for their approach, and demonstrate that the independent ethics committee or institutional review board explicitly approved the doubtful aspects of the study.

If a study was granted exemption from requiring ethics approval, this should also be detailed in the manuscript (including the name of the ethics committee that granted the exemption and the reasons for the exemption).

Authors must - in all situations as described above - include the name of the ethics committee and the reference number where appropriate.

See below examples:

**Ethical approval:** “All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (include name of committee + reference number) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.”

### **Ethical approval of studies using pre-existing data**

Data should be anonymized and irreversibly de-identified to protect patient, health care professional and/or hospital privacy. For studies using pre-existing and de-identified data, formal approval from the ethics committee is not required.

### **Informed consent**

All individuals have individual rights that are not to be infringed. Individual participants in studies have, for example, the right to decide what happens to the (identifiable) personal data gathered, to what they have said during a study or an interview, as well as to any photograph that was taken. Hence it is important that all participants gave their informed consent in writing prior to inclusion in the study. Identifying details (names, dates of birth, identity numbers and other information) of the participants that were studied should not be published in written descriptions, photographs, and genetic profiles unless the information is essential for scientific purposes and the participant (or parent or guardian if the participant is incapable) gave written informed consent for publication. Complete anonymity is difficult to achieve in some cases, and informed consent should be obtained if there is any doubt. For example, masking the eye region in photographs of participants is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic profiles, authors should provide assurance that alterations do not distort scientific meaning. The following statement should be included:

**Informed consent:** “Informed consent was obtained from all individual participants included in the study.”

If identifying information about participants is available in the article, the following statement should be included: “Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.”

**An ethics questionnaire is a mandatory feature of the submission system. Please ensure that the relevant ethical approval and consent details were received and are available on request by the editor or editorial office. You will be requested to declare involvement of any human or animal subjects, and inclusion of identifiable human data for the research during the submission process; declaration statements will be generated and automatically added to your manuscript.**

### **Ethical responsibilities of authors**

Please read carefully the following sections about ethical responsibilities of authors. Submissions that do not meet all of the ethical requirements are returned to the author

shortly after submission or rejected immediately. Co-authorship should fully comply with the four criteria defined by the [ICMJE guidelines](#).

This journal is committed to upholding the integrity of the scientific record. The publisher of PHR, Frontiers, is a member of the Committee on Publication Ethics (COPE) and thus the journal will follow the COPE guidelines on how to deal with potential acts of misconduct. Authors should refrain from misrepresenting research results which could damage the trust in the journal, the professionalism of scientific authorship, and ultimately the entire scientific endeavor. Maintaining integrity of the research and its presentation is helped by following the rules of good scientific practice, which include\*:

- The manuscript should not be submitted to more than one journal for simultaneous consideration.
- The submitted work should be original and should not have been published elsewhere in any form or language (partially or in full), unless the new work concerns an expansion of previous work. (Please provide transparency on the re-use of material to avoid the concerns about text-recycling ('self-plagiarism').
- A single study should not be split up into several parts to increase the quantity of submissions and submitted to various journals or to one journal over time (i.e. 'salami-slicing/publishing').
- Concurrent or secondary publication is sometimes justifiable, provided certain conditions are met. Examples include translations or a manuscript that is intended for a different group of readers.
- Results should be presented clearly, honestly, and without fabrication, falsification or inappropriate data manipulation (including image based manipulation). Authors should adhere to discipline-specific rules for acquiring, selecting and processing data.
- No data, text, or theories by others are presented as if they were the author's own ('plagiarism'). Proper acknowledgements to other works must be given (this includes material that is closely copied (near verbatim), summarized and/or paraphrased), quotation marks (to indicate words taken from another source) are used for verbatim copying of material, and permissions secured for material that is copyrighted.
- **Important note: the journal uses software to screen all submissions and revised versions for plagiarism.**
- Authors should make sure they have permissions for the use of software, questionnaires/(web) surveys and scales in their studies (if appropriate).
- Authors should avoid untrue statements about an entity (who can be an individual person or a company) or descriptions of their behavior or actions that could potentially be seen as personal attacks or allegations about that person.
- Research that may be misapplied to pose a threat to public health or national security should be clearly identified in the manuscript (e.g. dual use of research). Examples include the creation of harmful consequences of biological agents or toxins, disruption of immunity of vaccines, unusual hazards in the use of chemicals, weaponization of research/technology (amongst others).
- Authors are strongly advised to ensure the author group, the Corresponding Author, and the order of authors are all correct at submission. Adding and/or

deleting authors during the revision stages is generally not permitted, but in some cases may be warranted. Reasons for changes in authorship should be explained in detail. Please note that changes to authorship cannot be made after acceptance of a manuscript.

Upon request, authors should be prepared to send relevant documentation or data in order to verify the validity of the results presented. This could be in the form of raw data, samples, records, etc. Sensitive information in the form of confidential or proprietary data is excluded. \*All of the above are guidelines and authors need to make sure to respect third parties' rights such as copyright and/or moral rights.

If there is suspicion of misbehavior or alleged fraud the Journal and/or Publisher will carry out an investigation following COPE guidelines. If, after investigation, there are valid concerns, the author(s) concerned will be contacted under their given e-mail address and given an opportunity to address the issue. Depending on the situation, this may result in the Journal's and/or Publisher's implementation of the following measures, including, but not limited to:

- If the manuscript is still under consideration, it may be rejected and returned to the author.
- If the article has already been published online, depending on the nature and severity of the infraction:
  - a Correction may be placed with the article
  - an expression of concern may be placed with the article
  - in severe cases retraction of the article may occur. The reason will be given in the published erratum, expression of concern or retraction note, which will accompany the original article. Please note that retraction means that the article is maintained on the platform, watermarked "retracted" and the explanation for the retraction is provided in a note linked to the watermarked article.
- The author's institution may be informed
- A notice of suspected transgression of ethical standards in the peer review system may be included as part of the author's and article's bibliographic record.

## Proof reading

The purpose of the proof is to check for typesetting or conversion errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor.

After online publication, further changes can only be made in the form of a Correction, which will be hyperlinked to the article.

**To avoid a Correction connected to your article, please correct proofs very thoroughly (numbers and data in all tables and figures, title, author names and**

**affiliations, all references). Please note, even small changes are not possible after online publication.**

## **English language editing**

For editors and reviewers to accurately assess the work presented in your manuscript you need to ensure the English language is of sufficient quality to be understood. If you need help with writing in English, you should consider:

- Asking a colleague who is a native English speaker to review your manuscript for clarity.
- Using a professional language editing service where editors will improve the English to ensure that your meaning is clear and identify problems that require your review.

Please note that the use of a language editing service is not a requirement for publication in this journal and does not imply or guarantee that the article will be selected for peer review or will be accepted for publication.

If your manuscript is accepted, it will be checked by our copyeditors for spelling and formal style before publication.